Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Mary E. Willy"'
Autor:
Esther H. Zhou, Tracy M. Pham, Mary E. Willy, Hina Mehta, Solomon Iyasu, Judy A. Staffa, Hui-Lee Wong, Yulan Ding, Jacqueline M. Major, Cunlin Wang, James Phillip Trinidad
Publikováno v:
Pharmacoepidemiology and Drug Safety. 25:590-598
PURPOSE: The goal of this study is to summarize trends in rates of adverse events attributable to acetaminophen use, including hepatotoxicity and mortality. METHODS: A comprehensive analysis of data from three national surveillance systems estimated
Publikováno v:
Pharmacoepidemiology and Drug Safety. 24:518-525
PURPOSE: When a Medication Guide (MG) is part of Risk Evaluation and Mitigation Strategy (REMS), manufacturers assess the effectiveness of MGs through patient surveys, which have not undergone systematic evaluation. We aimed to characterize knowledge
Autor:
Mary E. Willy, Esther H. Zhou, Daniel S. Budnitz, Maribeth C. Lovegrove, Angelika D. Manthripragada
Publikováno v:
Pharmacoepidemiology and Drug Safety. 20:819-826
PURPOSE: To estimate the number of acetaminophen overdose-related emergency department (ED) visits and hospitalizations in the United States, characterize these by intentionality, age, and gender, and compare the strengths and limitations of the util
Autor:
David Kaufman, Parivash Nourjah, Mary E. Willy, Daniel S. Budnitz, Judith P. Kelly, Judy A. Staffa
Publikováno v:
Pharmacoepidemiology and Drug Safety. 18:188-195
Purpose To estimate the rate of emergency department (ED) visits attributed to selected analgesic-containing medications. Methods We used a nationally representative public health surveillance system to provide estimates of adverse events identified
Publikováno v:
Journal of the American Pharmacists Association. 48:494-500
Objectives: To gain insight on the knowledge, opinions, barriers, and practices of pharmacists regarding drug risk-minimization tools. Design: Descriptive, nonexperimental, cross-sectional survey. Setting: 20 states in the United States, fall 2004. P
Publikováno v:
The AAPS Journal. 10:35-41
The safety profile of newly approved drugs and therapeutic biologics is less well developed by pre-marketing clinical testing than is the efficacy profile. The full safety profile of an approved product is established during years of clinical use. Fo
Publikováno v:
Pharmacoepidemiology and Drug Safety. 15:398-405
Objective To estimate the number of acetaminophen-associated overdoses in the United States and identify possible risk factors for intervention. Methods The investigators obtained estimates of acetaminophen-associated overdoses using different nation
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 41:785-790
Objective To assess compliance with product labeling recommendations to use pemoline as second-line therapy for attention-deficit/hyperactivity disorder (ADHD) and to obtain baseline and biweekly liver enzyme tests. Method Retrospective cohort study
Autor:
David J. Graham, Mary E. Willy, Judith A. Racoosin, Rajdeep Gill, Jeff Yang, Joyce Choi, Chris Worrall, Jessica C. Young, Garner F. Kropp, Thomas E. MaCurdy, Jeffrey A. Kelman
Publikováno v:
Pain medicine (Malden, Mass.). 15(9)
Objective The objective of this study was to develop metrics to assess opioid prescribing behavior as part of the evaluation of the Extended-Release/Long-Acting (ER/LA) Opioid Analgesic Risk Evaluation and Mitigation Strategies (REMS). Design Candida
Autor:
James F. Lloyd, Matthew H. Samore, Rouett Abouzelof, Don A. Woodbury, Reed M. Gardner, R. Scott Evans, Roselie A. Bright, Patricia Gould, Carrie Taylor, April Lassen, Mary E. Willy
Publikováno v:
Obstetrical & Gynecological Survey. 59:342-344
ContextAlthough adverse drug events have been extensively evaluated by computer-based surveillance, medical device errors have no comparable surveillance techniques.ObjectivesTo determine whether computer-based surveillance can reliably identify medi